Fluidigm and Ascendas Genomics Announce Strategic Partnership to Develop Microfluidic Molecular Diagnostics in China
SOUTH SAN FRANCISCO, Calif. and ZHONGSHAN, China, July 27, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) and Ascendas Genomics today announced a strategic partnership to develop molecular diagnostics in China. Under the terms of the partnership, Ascendas Genomics will develop and commercialize molecular diagnostic systems and assays in China using microfluidic technologies included in the Fluidigm® Biomark™ HD and Juno™ systems. Fluidigm’s microfluidic technology enables... Read more